17 beta-Hydroxysteroid dehydrogenase (17 beta-HSD) controls the last s
tep in the formation of all androgens and all estrogens. This crucial
role of 17 beta-HSD is performed by at least five 17 beta-HSD isoenzym
es having individual cell-specific expression, substrate specificity,
regulation mechanisms, and reductive or oxidative catalytic activity.
Both estrogenic and androgenic 17 beta-HSD activities were found in al
l 25 rhesus monkey and 15 human peripheral intracrine tissues examined
. Type 1 17 beta-HSD is a protein of 327 amino acids catalyzing the fo
rmation of 17 beta-estradiol from estrone. Its x-ray structure was the
first to be determined among mammalian steroidogenic enzymes. Initial
ly crystallized with NAD, the crystal structure of type 1 17 beta-HSD
has just been determined as a complex with 17 beta-estradiol, thereby
illustrating the conformation of the substrate-binding site. Type 2 17
beta-HSD degrades 17 beta-estradiol into estrone and testosterone int
o androstenedione, and type 4 17 beta-HSD mainly degrades 17 beta-estr
adiol into estrone and androst-5-ene-3 beta, 17 beta-diol into dehydro
epiandrosterone. Types 3 and 5 17 beta-HSD, on the other hand, catalyz
e the formation of testosterone from androstenedione in the testis and
peripheral tissues, respectively. The various types of human 17 beta-
HSD, because of their tissue-specific expression and substrate specifi
city, provide each peripheral cell with the necessary mechanisms to co
ntrol the level of intracellular androgens and/or estrogens, a new are
a of hormonal control that we call intracrinology. (C) 1997 by Elsevie
r Science Inc.